Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

 

April 11, 2017

Date of report (Date of earliest event reported)

 

---

 

Agile Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

---

 

Delaware		001-36464		23-2936302
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

101 Poor Farm Road Princeton, New Jersey (Address of principal executive offices)

08540 (Zip Code)

 

Registrant’s telephone number, including area code [phone]

 

 

(Former name or former address, if changed since last report)

 

---

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Item 8.01.   Other Events.

 

On April 11, 2017, Agile Therapeutics, Inc. (“Agile”) issued a press release announcing that Agile has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) for its recent pre-New Drug Application (NDA) submission meeting on its lead product candidate, Twirla ® , a once-weekly prescription contraceptive patch.

 

A copy of Agile’s press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein.

 

Item 9.01.      Financial Statements and Exhibits.

 

(d)            Exhibits.

 

Exhibit Number		Description
99.1		Agile Therapeutics, Inc. Press Release dated April 11, 2017 relating to the results of the Company’s pre-New Drug Application (NDA) submission meeting with the FDA.

 

2

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Agile Therapeutics, Inc.
Dated: April 11, 2017	By:	/s/ Alfred Altomari
	Name:	Alfred Altomari
	Title:	Chairman and Chief Executive Officer

 

3

---